A practical reference on Drug affinity complex: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Successful bead beating is dependent not only on design features of the shaking machine (which take into consideration shaking oscillations frequency, shaking throw or distance, shaking orientation and vial orientation), but also the selection of correct bead size (0.1–6 mm (0.004–0.2 in) diameter), bead composition (glass, ceramic, steel) and bead load in the vial. In most laboratories, bead beating is done in batch sizes of one to twenty-four sealed, plastic vials or centrifuge tubes. The sample and tiny beads are agitated at about 2000 oscillations per minute in specially designed reciprocating shakers driven by high power electric motors. Cell disruption is complete in 1–3 minutes of shaking. Significantly faster rates of cell disruption are achieved with a bead beater variation called SoniBeast. Differing from conventional machines, it agitates the beads using a vortex motion at 20,000 oscillations per minute. Larger bead beater machines that hold deep-well microtiter plates also shorten process times, as do Bead Dispensers designed to quickly load beads into multiple vials or microplates. Pre-loaded vials and microplates are also available. All high energy bead beating machines warm the sample about 10 degrees per minute. This is due to frictional collisions of the beads during homogenization. Cooling of the sample during or after bead beating may be necessary to prevent damage to heat-sensitive proteins such as enzymes.
In June 2026, progressive political commentator Ta-Nehisi Coates published a Vanity Fair article entitled Did Kamala Harris's Silence on Gaza Cost Her the White House? He argued the US adhered to a "survivalist theory of democracy" and that there was a "bipartisan acceptance of innocent death as the cost of doing business in the Muslim and Arab world," including with respect to the Gaza war and genocide. He said this led to a "casual contempt" for Democrat leaders. He also referenced how the Democratic Party had refused to allow a Palestinian American to speak at the 2024 Democratic National Convention. He also argued the election was a matter of lesser-evil voting. Journalist Joy Reid claimed many African Americans could not connect with Harris due to "her sort of political inability to speak directly to the genocide."
=== EC 1.13.11 With incorporation of two atoms of oxygen === EC 1.13.11.1: catechol 1,2-dioxygenase EC 1.13.11.2: catechol 2,3-dioxygenase EC 1.13.11.3: protocatechuate 3,4-dioxygenase EC 1.13.11.4: gentisate 1,2-dioxygenase EC 1.13.11.5: homogentisate 1,2-dioxygenase EC 1.13.11.6: 3-hydroxyanthranilate 3,4-dioxygenase EC 1.13.11.7: deleted EC 1.13.11.8: protocatechuate 4,5-dioxygenase EC 1.13.11.9: 2,5-dihydroxypyridine 5,6-dioxygenase EC 1.13.11.10: 7,8-dihydroxykynurenate 8,8a-dioxygenase EC 1.13.11.11: tryptophan 2,3-dioxygenase EC 1.13.11.12: linoleate 13S-lipoxygenas EC 1.13.11.13: The activity is the sum of several enzymatic and spontaneous reactions EC 1.13.11.14: 2,3-dihydroxybenzoate 3,4-dioxygenase EC 1.13.11.15: 3,4-dihydroxyphenylacetate 2,3-dioxygenase EC 1.13.11.16: 3-carboxyethylcatechol 2,3-dioxygenase EC 1.13.11.17: indole 2,3-dioxygenase EC 1.13.11.18: persulfide dioxygenase EC 1.13.11.19: cysteamine dioxygenase EC 1.13.11.20: cysteine dioxygenase EC 1.13.11.21: Now EC 1.14.99.36, β-carotene 15,15′-monooxygenase EC 1.13.11.22: caffeate 3,4-dioxygenase EC 1.13.11.23: 2,3-dihydroxyindole 2,3-dioxygenase EC 1.13.11.24: quercetin 2,3-dioxygenase EC 1.13.11.25: 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 4,5-dioxygenase EC 1.13.11.26: peptide-tryptophan 2,3-dioxygenase EC 1.13.11.27: 4-hydroxyphenylpyruvate dioxygenase EC 1.13.11.28: 2,3-dihydroxybenzoate 2,3-dioxygenase EC 1.13.11.29: stizolobate synthase EC 1.13.11.30: stizolobinate synthase EC 1.13.11.31: arachidonate 12-lipoxygenase EC 1.13.11.32: Now EC 1.13.12.16, nitronate monooxygenase EC 1.13.11.33: arachidonate 15-lipoxygenase EC 1.13.11.34: arachidonate 5-lipoxygenase EC 1.13.11.35: pyrogallol 1,2-oxygenase EC 1.13.11.36: chloridazon-catechol dioxygenase EC 1.13.11.37: hydroxyquinol 1,2-dioxygenase EC 1.13.11.38: 1-hydroxy-2-naphthoate 1,2-dioxygenase EC 1.13.11.39: biphenyl-2,3-diol 1,2-dioxygenase EC 1.13.11.40: arachidonate 8-lipoxygenase EC 1.13.11.41: 2,4′-dihydroxyacetophenone dioxygenase EC 1.13.11.42: identical to EC 1.13.11.11, tryptophan 2,3-dioxygenase EC 1.13.11.43: lignostilbene αβ-dioxygenase EC 1.13.11.44: Activity is covered by EC 1.13.11.60, linoleate 8R-lipoxygenase and EC 5.4.4.6, 9,12-octadecadienoate 8-hydroperoxide 8S-isomerase EC 1.13.11.45: linoleate 11-lipoxygenase EC 1.13.11.46: 4-hydroxymandelate synthase EC 1.13.11.47: 3-hydroxy-4-oxoquinoline 2,4-dioxygenase EC 1.13.11.48: 3-hydroxy-2-methyl-quinolin-4-one 2,4-dioxygenase EC 1.13.11.49: chlorite O2-lyase EC 1.13.11.50: acetylacetone-cleaving enzyme EC 1.13.11.51: 9-cis-epoxycarotenoid dioxygenase EC 1.13.11.52: indoleamine 2,3-dioxygenase EC 1.13.11.53: acireductone dioxygenase (Ni2+-requiring) EC 1.13.11.54: acireductone dioxygenase [iron(II)-requiring] EC 1.13.11.55: sulfur oxygenase/reductase EC 1.13.11.56: 1,2-dihydroxynaphthalene dioxygenase EC 1.13.11.57: gallate dioxygenase EC 1.13.11.58: linoleate 9S-lipoxygenase EC 1.13.11.59: torulene dioxygenase EC 1.13.11.60: inoleate 8R-lipoxygenase EC 1.13.11.61: linolenate 9R-lipoxygenase EC 1.13.11.62: linoleate 10R-lipoxygenase EC 1.13.11.63: β-carotene 15,15′-dioxygenase EC 1.13.11.64: 5-nitrosalicylate dioxygenase EC 1.13.11.65: carotenoid isomerooxygenase EC 1.13.11.66: hydroquinone 1,2-dioxygenase EC 1.13.11.67: 8′-apo-β-carotenoid 14′,13′-cleaving dioxygenase EC 1.13.11.68: 9-cis-β-carotene 9′,10′-cleaving dioxygenase EC 1.13.11.69: carlactone synthase EC 1.13.11.70: all-trans-10′-apo-β-carotenal 13,14-cleaving dioxygenase EC 1.13.11.71: carotenoid-9′,10′-cleaving dioxygenase EC 1.13.11.72: 2-hydroxyethylphosphonate dioxygenase EC 1.13.11.73: methylphosphonate synthase EC 1.13.11.74: 2-aminophenol 1,6-dioxygenase EC 1.13.11.75: all-trans-8′-apo-β-carotenal 15,15′-oxygenase EC 1.13.11.76: 2-amino-5-chlorophenol 1,6-dioxygenase EC 1.13.11.77: oleate 10S-lipoxygenase EC 1.13.11.78: 2-amino-1-hydroxyethylphosphonate dioxygenase (glycine-forming) EC 1.13.11.79: aerobic 5,6-dimethylbenzimidazole synthase EC 1.13.11.80: (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase EC 1.13.11.81: 7,8-dihydroneopterin oxygenase EC 1.13.11.82: 8′-apo-carotenoid 13,14-cleaving dioxygenase EC 1.13.11.83: 4-hydroxy-3-prenylphenylpyruvate oxygenase EC 1.13.11.84: crocetin dialdehyde synthase EC 1.13.11.85: exo-cleaving rubber dioxygenase EC 1.13.11.86: 5-aminosalicylate 1,2-dioxygenase EC 1.13.11.87: endo-cleaving rubber dioxygenase EC 1.13.11.88: isoeugenol monooxygenase EC 1.13.11.89: (hydroxymethyl)phosphonate dioxygenase EC 1.13.11.90: [1-hydroxy-2-(trimethylamino)ethyl]phosphonate dioxygenase (glycine-betaine-forming) EC 1.13.11.91: 3-mercaptopropionate dioxygenase EC 1.13.11.92: fatty acid α-dioxygenase
Sources: en.wikipedia.org
== Inhibition == Although cartilage breakdown is important for the metabolic process and removing dead cells, unregulated degradation can cause illness. The regulatory mechanisms in place are inhibitory proteins known as tissue inhibitors of metalloproteinases. A large contributor to the inhibition is TIMP3 halting enzymes ADAMTS4 and ADAMTS5. In order for TIMP3 to conduct its functions it binds to negatively charged components of the extracellular matrix allowing it to remain localized where aggrecan degradation occurs. The inhibition has been shown to be more of a reactionary response instead of a precautionary action. It increases its expression when conditions such as osteoarthritis is present. Along with the natural inhibition of TIMP3 scientist are conducting research to create synthetic inhibitors. This is a work in progress as the main issue is the inhibitors are not specific enough and are blocking other enzymes.
== Biosynthesis == In the morphine biosynthetic pathway, salutaridinol is derived in three steps from (R)-reticuline. First, (R)-reticuline undergoes an oxidation at each of its phenol rings mediated by the cytochrome P-450-dependent monooxygenase salutaridine synthase. These phenol group oxidations yield a diradical species that undergoes ortho coupling to the phenol group of the tetrahydroisoquinoline and para coupling to the benzyl group to create the salutaridinol precursor salutaridine. A stereospecific reduction of the salutaridine carbonyl group by salutaridine: NADPH 7-oxidoreductase then generates salutaridinol.
Direct regulation of translation is less prevalent than control of transcription or mRNA stability but is occasionally used. Inhibition of protein translation is a major target for toxins and antibiotics, so they can kill a cell by overriding its normal gene expression control. Protein synthesis inhibitors include the antibiotic neomycin and the toxin ricin.
A similar system achieves the same temporal control of condensate formation by using light-sensitive 'caged' dimerizers. In this case, light-activation removes the dimerizer cage, allowing it to recruit IDRs to multivalent cores, which then triggers phase separation. Light-activation of a different wavelength results in the dimerizer being cleaved, which then releases the IDRs from the core and consequentially dissolves the condensate. This dimerizer system requires significantly reduced amounts of laser light to operate, which is advantageous because high intensity light can be toxic to cells. Optogenetic systems can also be modified to gain spatial control over the formation of condensates. Multiple approaches have been developed to do so. In one approach, which localizes condensates to specific genomic regions, core proteins are fused to proteins such as TRF1 or catalytically dead Cas9, which bind specific genomic loci. When oligomerization is trigger by light activation, phase separation is preferentially induced on the specific genomic region which is recognized by fusion protein. Because condensates of the same composition can interact and fuse with each other, if they are tethered to specific regions of the genome, condensates can be used to alter the spatial organization of the genome, which can have effects on gene expression.
Sources: en.wikipedia.org
“A New Pentacyclic Pyrylium Fluorescent Probe that Responds to pH Imbalance During Apoptosis”. Chem. Sci., 2020,11, 12695-12700. https://doi.org/10.1039/D0SC02623A. A. Mal, S. Vijayakumar, R. K. Mishra, J. Jacob, R. S. Pillai, B. S. Dileep Kumar and Ajayaghosh, Ayyappanpillai (2020). “Supramolecular Surface Charge Regulation in Ionic Covalent Organic Nanosheets for Reversible Exfoliation and Controlled Bacterial Growth”. Angew. Chem., Int. Ed. 2020, 59, 8713-8719. https://doi.org/10.1002/anie.201912363. G, Das.; S, Cherumukkil.; A, Padmakumar.; V, B, Banakar.; V, K, Praveen.; and Ajayaghosh, Ayyappanpillai (2021). “Tweaking a BODIPY Spherical Self-Assembly to 2D Supramolecular Polymers Facilitates Excited State Cascade Energy Transfer”. Angew. Chem. Int. Ed. 2021, 60, 7851-7938. https://doi.org/10.1002/ange.202015390. A, Nirmala.; I, Mukkatt.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2021). “Thermochromic Color Switching to Temperature Controlled Volatile Memory and Counter Operations with Metal-Organic Complexes and Hybrid Gels”. Angew. Chem., Int. Ed. 2021, 60, 455-465. https://doi.org/10.1002/anie.202011580. I, Mukkatt.; A, P, Mohanachandran.; A, Nirmala.; D, Patra.; P, A, Sukumaran.; R, S, Pillai.; R, B, Rakhi.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2022). “Tunable Capacitive Behavior in Metallopolymer-based Electrochromic Thin Film Supercapacitors”. ACS Appl. Mater. Interfaces, 2022, 14, 31900-31910. https://doi.org/10.1021/acsami.2c05744
=== Brain === The brain parenchyma refers to the functional tissue in the brain that is made up of the two types of brain cell, neurons and glial cells. It is also known to contain collagen proteins. Damage or trauma to the brain parenchyma often results in a loss of cognitive ability or even death. Bleeding into the parenchyma is known as intraparenchymal hemorrhage.
=== Cardiac === SSRIs do not appear to affect the risk of coronary heart disease (CHD) in those without a previous diagnosis of CHD. A large cohort study suggested no substantial increase in the risk of cardiac malformations attributable to SSRI usage during the first trimester of pregnancy. A number of large studies of people without known pre-existing heart disease have reported no EKG changes related to SSRI use. The recommended maximum daily dose of citalopram and escitalopram was reduced due to concerns with QT prolongation. In overdose, fluoxetine has been reported to cause sinus tachycardia, myocardial infarction, junctional rhythms, and trigeminy. Some authors have suggested electrocardiographic monitoring in patients with severe pre-existing cardiovascular disease who are taking SSRIs. In a 2023 study, a possible connection between SSRI usage and the onset of mitral valve regurgitation was identified, indicating that SSRIs could hasten the progression of degenerative mitral valve regurgitation (DMR), especially in individuals carrying 5-HTTLPR genotype. The study's authors suggest that genotyping should be performed on people with DMR to evaluate serotonin transporter (SERT) activity. They also urge practitioners to exercise caution when prescribing SSRIs to individuals with a familial history of DMR.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.